Watertown, MA – According to filings with the U.S. Securities and Exchange Commission, Zikani Therapeutics is raising $7,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Sumit Aggarwal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Zikani Therapeutics

Zikani’s TURBO-ZM (Tuning the Ribosome with Zikani Molecules) is a proprietary platform that allows rapid synthesis of novel compounds that can be optimized to target the human ribosome in a disease specific manner. With TURBO-ZM, we can design novel oral ribosome modulating agents (RMAs) that can be tuned to deliver specific results. Zikani has an expanding library of these novel oral RMAs that have demonstrated strong activity across a range of diseases.

To learn more about Zikani Therapeutics, visit http://www.zikani.com/

Contact:
Sumit Aggarwal, President and Chief Executive Officer
617-229-6503
https://www.linkedin.com/in/sumitagg/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved